Novel avenues for treating diabetic nephropathy: new investigational drugs

References

• Herrera MB, Bussolati B, Bruno S, et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14:1035–1041.
   PubMed Web of Science ®Google Scholar
• Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14:631–640.
   PubMed Web of Science ®Google Scholar
• Ezquer F, Ezquer M, Simon V, et al. Endovenous administration of bone marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009;15:1354–1365.
   PubMed Web of Science ®Google Scholar
• Fang Y, Tian X, Bai S, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med. 2012;30:85–92.
   PubMed Web of Science ®Google Scholar
• Wans S, Li Y, Zhao J, et al. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 2013;19:538–546.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20:14–20.
   PubMed Web of Science ®Google Scholar
• Skyler JA, Fonseca VA, Segal KR, et al. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care. 2015;38:1742–1749.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90:1814–1818.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
   PubMed Web of Science ®Google Scholar
• Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol. 1997;52:77–78.
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906–913.
   PubMed Web of Science ®Google Scholar
• RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 2009;20:1765–1775.
   PubMed Web of Science ®Google Scholar
• Grattendick KJ, Nakashima JM, Feng L, et al. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol. 2008;8:679–687.
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446:167–176.
   PubMed Web of Science ®Google Scholar
• Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144–1151.
   PubMed Web of Science ®Google Scholar
• Insel P, Turner RE, Ross D. Water-soluble vitamins, in Nutrition. (MA): Jones and Bartlett Publishers; 2002.
   Google Scholar
• Jovanovic-Peterson J, Peterson CM. Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy, J. Am Coll Nutr. 1996;15:14–20.
   PubMed Web of Science ®Google Scholar
• Nair R, Biju MP, Paulose CS. Effect of pyridoxine and insulin administration on brain glutamate dehydrogenase activity and blood glucose control in streptozotocin-induced diabetic rats, Biochim. Biophys Acta Gen Subj. 1998;1381:351–354.
   PubMed Web of Science ®Google Scholar
• Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010;55:928–940.
   PubMed Web of Science ®Google Scholar
• Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61:939–950.
   PubMed Web of Science ®Google Scholar
• Tanimoto M, Gohda T, Kaneko S, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism. 2007;56:160–167.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:131–136.
   PubMed Web of Science ®Google Scholar
• Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605–614.
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Bore L, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:4233–4246.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005;102:4584–4589.
   PubMed Web of Science ®Google Scholar
• Yoh K, Itoh K, Enomoto A, et al. Nrf2- deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 2001;60:1343–1353.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, et al.; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327–336.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, Chertow GM, Akizawa T, et al. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013;28:2841–2850.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol. 2013;37:212–222.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al.; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–2503.
   PubMed Web of Science ®Google Scholar
• Chin MP, Reisman SA, Bakris GL, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014;396:499–508.
   Web of Science ®Google Scholar
• Gorin Y, Cavaglieri RC, Khazim K, et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol. 2015;308:F1276–F1287.
   PubMed Web of Science ®Google Scholar
• Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001;94:378–383.
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936–1939.
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012;29:e184–90.
   PubMed Web of Science ®Google Scholar
• Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open. 2016;6:e010310.
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117–123.
   PubMed Web of Science ®Google Scholar
• Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73–84.
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Kobori H, Konishi Y, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332:1072–1080.
   PubMed Web of Science ®Google Scholar
• Zhou G, Johansson U, Peng XR, et al. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res. 2016 Mar;15(8):1339–1354.
   Google Scholar
• Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens. 2002;15:24A.
   PubMed Web of Science ®Google Scholar
• L Cy L, Shutte E, Gansevoort RT, et al. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015;24:1–13.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884–894.
   PubMed Web of Science ®Google Scholar
• Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150,a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226–234.
   PubMed Web of Science ®Google Scholar
• Arai K, Morikawa Y, Ubukata N, et al. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in DOCA/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548–557.
   PubMed Web of Science ®Google Scholar
• Orena S, Maurer TS, She L, et al. PF-03882845,a non-steroidal Mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol. 2013;4:1–11.
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398–2404.
   PubMed Web of Science ®Google Scholar
• Zhou G, Liu X, Cheung AK, et al. Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? Am J Transl Res. 2015;7:825–840.
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–2213.
   PubMed Web of Science ®Google Scholar
• Soga M, Matsuzawa A, Ichijo H. Oxidative stress-induced diseases via the ASK1 signaling pathway. Int J Cell Biol. 2012;2012:439587.
   PubMedGoogle Scholar
• Tesch GH, Ma FY, Han Y, et al. ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice. Diabetes. 2015;64:3903-3913.
   Google Scholar
• Karamouzis I, Sarafidis PA, Karamouzis M, et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol. 2008;28:397–404.
   PubMed Web of Science ®Google Scholar
• Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752–760.
   PubMed Web of Science ®Google Scholar
• Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394.
   PubMed Web of Science ®Google Scholar
• Leyva-Jiménez R, Rodríguez-Orozco AR, Ortega-Pierres LE, et al. Effect of pentoxifylline on the evolution of diabetic nephropathy. Med Clin (Barc). 2009;132:772–778.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26:220–229.
   PubMed Web of Science ®Google Scholar
• Tang WH, Lin FH, Lee CH, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine. 2014;45:293–301.
   PubMed Web of Science ®Google Scholar
• Sabounjian LA, Graham P, Wu L. A first-in-patient, multicenter, double-blind, 2-arm, placebo-controlled, randomized safety and tolerability study of a novel oral drug candidate,CTP-499, in chronic kidney disease. Clin Pharmacol Drug Dev. 2016;5:314–325.
   PubMed Web of Science ®Google Scholar
• Scheele W, Diamond S, Gale J. Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol. 2016;27:3459–3468.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647–F657.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Bustos C, Alonso J, et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp. 1995;24:53–77.
   PubMedGoogle Scholar
• Moreno JA, Moreno S, Rubio-Navarro A, et al. Role of chemokines in proteinuric kidney disorders. Expert Rev Mol Med. 2014;16:e3.
   PubMed Web of Science ®Google Scholar
• Sayyed SG, Ryu M, Kulkarni OP, et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 2011;80:68–78.
   PubMed Web of Science ®Google Scholar
• Sullivan TJ, Miao Z, Zhao BN, et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism. 2013;62:1623–1632.
   PubMed Web of Science ®Google Scholar
• Norman P. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011;21:1919–1924.
   PubMed Web of Science ®Google Scholar
• Sullivan T, Miao Z, Dairaghi DJ, et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol. 2013;305:F1288–F1297.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 2015;3:687–696.
   PubMed Web of Science ®Google Scholar
• Mora E, Guglielmotti A, Biondi G, et al. Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway. Cell Cycle. 2012;11:159–169.
   PubMed Web of Science ®Google Scholar
• Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther. 1991;51:377–401.
   PubMed Web of Science ®Google Scholar
• Oner A, Erdogan O, Demircin G, et al. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18:521–526.
   PubMed Web of Science ®Google Scholar
• Santoro D, Postorino A, Costa S, et al. Renal amyloidosis in cystic fibrosis: role of colchicine therapy. Clin Kidney J. 2014;7:81–82.
   PubMedGoogle Scholar
• Li C, Yang CW, Ahn HJ, et al. Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity. J Lab Clin Med. 2002;139:364–371.
   PubMed Web of Science ®Google Scholar
• Li JJ, Lee SH, Kim DJ, et al. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy. Am J Physiol Renal Physiol. 2009;297:F200–9.
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13:325–349.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang J, Yi B, et al. BsmI polymorphisms in vitamin D receptor gene are associated with diabetic nephropathy in type 2 diabetes in the Han Chinese population. Gene. 2012;495:183–188.
   PubMed Web of Science ®Google Scholar
• Santoro D, Caccamo D, Gagliostro G, et al. Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients. J Nephrol. 2013;26:636–644.
   PubMed Web of Science ®Google Scholar
• Santoro D, Gagliostro G, Alibrandi A, et al. Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease. Nutrients. 2014;10(6):1029–1037.
   Web of Science ®Google Scholar
• Lucisano S, Buemi M, Passantino A, et al. New insights on the role of vitamin D in the progression of renal damage. Kidney Blood Press Res. 2013;37:667–678.
   PubMed Web of Science ®Google Scholar
• Santoro D, Gitto L, Ferraro A, et al. Vitamin D status and mortality risk in patients with chronic kidney disease. Ren Fail. 2011;33:184–191.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. KidneyInt. 2008;73:163–171.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deb DK, Zhang Z, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012;23:1977–1986.
   PubMed Web of Science ®Google Scholar
• Yi B, Huang J, Zhang W, et al. Vitamin D receptor down-regulation is associated with severity of albuminuria in type 2 diabetes patients. J Clin Endocrinol Metab. 2016;101:4395–4404.
   PubMed Web of Science ®Google Scholar
• Krairittichai U, Mahannopkul R, Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai. 2012;95:S41–S47.
   PubMedGoogle Scholar
• Lucisano S, Arena A, Stassi G, et al. Role of paricalcitol in modulating the immune response in patients with renal disease. Int J Endocrinol. 2015;2015:765364.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543–1551.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 2011;80:851–860.
   PubMed Web of Science ®Google Scholar
• Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes. 2009;58:469–477.
   PubMed Web of Science ®Google Scholar
• Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol. 2010;21:763–772.
   PubMed Web of Science ®Google Scholar
• Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. Diabetologia. 2016;59:1624–1627.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-B in patients with DKD and type 2 diabetes. Diabetes Care. 2007;30:995–996.
   PubMed Web of Science ®Google Scholar
• Tuttle KG, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686–2690.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol. 2007;2:631–636.
   PubMed Web of Science ®Google Scholar
• Al-Onazi AS, Al-Rasheed NM, Attia HA, et al. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. J Pharm Pharmacol. 2016;68:219–232.
   PubMed Web of Science ®Google Scholar
• Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab. 2007;21:687–710.
   PubMed Web of Science ®Google Scholar
• Massaro M, Scoditti E, Pellegrino M, et al. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes. Pharmacol Res. 2016;107:125–136.
   PubMed Web of Science ®Google Scholar
• Boden G, Homko C, Mozzoli M, et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes. 2007;56:248–255.
   PubMed Web of Science ®Google Scholar
• Oakes ND, Thale´N P, Hultstrand T, et al. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2005;289:R938–46.
   PubMed Web of Science ®Google Scholar
• Zadelaar AS, Boesten LS, Jukema JW, et al. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arteriosclerosis Thromb Vasc Biol. 2006;26:2560–2566.
   PubMed Web of Science ®Google Scholar
• Ruilope L, Hanefeld M, Lincoff AM, et al. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014;18;15:180.
   Web of Science ®Google Scholar
• Hamrén B, Ohman KP, Svensson MK, et al. Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:1317–1327.
   PubMed Web of Science ®Google Scholar
• Hamrén B, Ericsson H, Samuelsson O, et al. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function–evidence of interconversion. Br J Clin Pharmacol. 2008;65:855–863.
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Rosenstock J, Anzalone D, et al. Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes. Annual Meeting of American Diabetes Association; 10-14 June 2005; San Diego; 2005. abstract 83-OR.
   Google Scholar
• Goldstein BJ, Rosenstock J, Anzalone D, et al. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin. 2006;22:2575-2590.
   Google Scholar
• Rubenstrunk A, Hanf R, Hum DW. et al. Safety issues and prospects for future generations of PPAR modulators. Biochimica Et Biophysica Acta. 2007;1771:1065–1081.
   PubMed Web of Science ®Google Scholar
• Fievet C, Fruchart JC, Staels B. PPARa and PPARg dual agonists for the treatment of type-2 diabetes and the metabolic syndrome. Curr Opin Pharmacol. 2006;6:606–614.
   PubMed Web of Science ®Google Scholar
• Santoro D, Pellicanò V, Visconti L, et al. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opin Biol Ther. 2015;15:1119–1143.
   PubMed Web of Science ®Google Scholar
• Yoon S, Gingras D, Bendayan M. Alterations of vitronectin and its receptor alpha(v) integrin in the rat renal glomerular wall during diabetes. Am J Kidney Dis. 2001;38:1298–1306.
   PubMed Web of Science ®Google Scholar
• Maile LA, Busby WH, Gollahon KA, et al. Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology. 2014;155:4665–4675.
   PubMed Web of Science ®Google Scholar
• Wahab NA, Schaefer L, Weston BS, et al. Glomerular expression of thrombospondin-1, TGF-beta and CTGF at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetalogica. 2005;48:2650–2660.
   PubMed Web of Science ®Google Scholar
• van Nieuwenhoven FA, Jensen LJN, Flyvbjerg A, et al. Imbalance of growth factor signalling in diabetic kidney disease: is CTGF (CCN2) the perfect intervention point? Nephrol Dial Transplant. 2005;20:6–10.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Akdeniz A, Weitz S, et al. Urinary CTGF excretion in patients with type 1 diabetes and nephropathy. Diabetes Care. 2003;26:2632–2636.
   PubMed Web of Science ®Google Scholar
• Adler SG, Schwartz S, Williams ME, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol. 2010;5:1420–1428.
   PubMed Web of Science ®Google Scholar
• Beidler CB, Petrovan RJ, Conner EM, et al. Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin. J Pharmacol Exp Ther. 2014;349:330–343.
   PubMed Web of Science ®Google Scholar
• Cohen MP, Ziyadeh FN, Hong SW, et al. Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF- 1. Kidney Int. 2002;61:2025–2032.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Han D, Cohen JA, et al. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor- system. Kidney Int. 1998;53:631–638.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Solano MP, Meneghini L, et al. Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. Am J Nephrol. 2010;31:110–116.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol. 2013;76:573–579.
   PubMed Web of Science ®Google Scholar
• Luscher TF. Barton M: endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434–2440.
   PubMed Web of Science ®Google Scholar
• Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol. 2008;4:490–501.
   PubMedGoogle Scholar
• Yamauchi T, Ohnaka K, Takayanagi R, et al. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett. 1990;267:16–18.
   PubMed Web of Science ®Google Scholar
• Cernaro V, Trifirò G, Lorenzano G, et al. New therapeutic strategies under development to halt the progression of renal failure. Expert Opin Investig Drugs. 2014;23:693–709.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pritchett Y, Molitch ME, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22:763–772.
   PubMed Web of Science ®Google Scholar
• Benigni A, Colosio V, Brena C, et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes. 1998;47:450–456.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25:1083–1093.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Lambers Heerspink HJ, Coll B, et al. Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy. Clin J Am Soc Nephrol. 2015;10:1568–1574.
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20:224–235.
   PubMed Web of Science ®Google Scholar
• Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res. 2011;2011:162092.
   PubMedGoogle Scholar
• Marques C, Mega C, Gonçalves A, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm. 2014;2014:538737.
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58:69–73.
   PubMed Web of Science ®Google Scholar
• Fujita H, Taniai H, Murayama H, et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr J. 2014;61:159–166.
   PubMed Web of Science ®Google Scholar
• Haluzík M, Frolík J, Rychlík I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol. 2013;2013:895102.
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;13(51):1145–1149.
   Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–2224.
   PubMed Web of Science ®Google Scholar
• Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–545.
   PubMed Web of Science ®Google Scholar
• Maldonado-Cervantes MI, Galicia OG, Moreno-Jaime B, et al. Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-alpha in LLCPK(1) cells. J Physiol Biochem. 2012;68:411–420.
   PubMed Web of Science ®Google Scholar
• Mather AJPK, Mudaliar H, Pollock CA, et al. Renoprotection with sodium glucose cotransporter 2 inhibition [abstract]. In: Renal Laboratory, Kolling Institute, Sydney, NSW, Australia. ASN Kidney week. Philadelphia (PA): ASN; 2011.
   Google Scholar
• Osorio H, Bautista R, Rios A, et al. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract. 2009;86:e46–9.
   PubMed Web of Science ®Google Scholar
• Pollock CA, Lawrence JR, Field MJ. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol. 1991;260:F946–52.
   PubMed Web of Science ®Google Scholar
• Vestri S, Okamoto MM, de Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001;182:105–112.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;28(375):323–334.
   Web of Science ®Google Scholar
• Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590–597.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76:432–444.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Seed A, Kuc RE, Maguire JJ, et al. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012;15(91):743–748.
   Web of Science ®Google Scholar
• Thöne-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44:S76–S79.
   PubMed Web of Science ®Google Scholar
• Parvanova A, van der Meer IM, Iliev I, et al. Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:19–27.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207:16–23.
   PubMed Web of Science ®Google Scholar
• Jeon SM, Park YB, Kwon OS, et al. Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol. J Biochem Mol Toxicol. 2005;19:336–346.
   PubMed Web of Science ®Google Scholar
• Jin SM, Han KA, Yu JM, et al. Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade: A 16-week, randomized, double-blind, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2016;36:2108–2114.
   PubMed Web of Science ®Google Scholar